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Gene delivery systems (GDS) play a central role in the development of gene therapy strategies for Cystic Fibrosis (CF). Further, these
systems are important tools in studies with cultured cells and in animal models. In this review, we describe the properties of several viral and
synthetic gene delivery systems, and evaluate their possible application in gene therapy of CF. While many gene delivery systems give
satisfactory results in cultured or animal studies, none of these systems has been shown to fulfil all the requirements of safety and efficacy for
use in CF patients. The intact airway epithelium, the most important target in CF gene therapy, proves to be well protected against invading
vector systems.
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Since the discovery of the CFTR gene in 1989 [1], many
attempts were made to develop a gene transfer system for
somatic gene therapy of CF. Cystic Fibrosis (CF) is a
recessive disorder, which implies that a single copy of the
normal CF gene is sufficient for normal function. Hence, the
concept of somatic CF gene therapy is deceptively simple.
All we have to do is to supply the affected cells with a gene
that expresses CFTR protein. The airway epithelium is the
most important target, as lung disease contributes mainly to
morbidity and mortality in CF patients. For this purpose,
many different gene delivery systems (GDS), viral and
synthetic, have been developed and investigated for efficacy
in vitro and in vivo. So far, what we have learned is that a
good gene transfer system in vitro is not necessarily a useful1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.05.042
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E-mail address: b.scholte@erasmusmc.nl (B.J. Scholte).gene therapy vector. Systemic application of vectors in a
clinical setting is much more challenging than transfection
of cells in a dish. Initial optimism about the use of
adenoviral vectors was weakened by their lack of transduc-
tion efficiency in intact human lung, and by safety concerns
caused by the inflammation response that was observed.
Trials with cationic liposomes showed low toxicity, but also
low efficacy. In addition, long-term stability and regulated
expression in a tissue-specific manner requires not only the
coding portions of the CFTR gene but also regulatory and
functional chromosomal elements. This is a requirement that
available vectors do not address.
A decade of vector development since the initial trials
has not yet yielded a vector that can be used successfully
to treat CF in the clinic [2–4]. However, many of the
available systems can be very useful for CF researchers
in animal models or in cultured cells in vitro. The
European Working Group on CFTR Expression website
provides a number of protocols and contacts that may
help researchers along [5]. Further, developments in the
field of vector development have raised new hope for
future clinical applications. This is the main thrust of this
review.ed by Elsevier B.V. All rights reserved.
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chronic lung disease
Airway epithelium, the most important target of CF gene
therapy and related research models is a highly complex,
multifunctional tissue. It lines the tubular structure of the
airways from the nasal cavity, via the trachea into the
intricately branched structure of the bronchial tree. It con-
sists of several epithelial cell types, which show marked
proximal to distal gradients. These include mucus secreting
(goblet) cells that produce a protective coating, ciliated cells
that are involved in clearance of bacterial pathogens and
other microscopic particles. Further distally, bronchi and
broncheoli are lined by CLARA cells, which secrete a
mixture of proteins and peptides that is presumably involved
in regulating inflammatory responses. Further, submucosal
glands produce a mixture of mucous and serous secretions
that is extremely important in lung homeostasis. In between
these prominent and well-known cell types, we find basal
cells and neuroendocrine cells. Further, there are cells that
do not belong to the epithelial lineage, such as macrophages
and dendritic cells, but which do contribute to the responses
of the tissue. Finally, it should be noted that this epithelial
layer grows on a complex matrix, which is produced by
mesenchymal cells. The dynamic cross-talk between epi-
thelium and mesenchyme, which can lead to irreversible and
pathological tissue remodelling (fibrosis), plays a key role in
CF lung pathology. While massive efforts are made to
elucidate the molecular basis of this process, and the role
that CFTR dysfunction plays, we are a long way from a
comprehensive model that could be used as a guide towards
therapeutic approaches.
Thus, the gene therapist is faced with an incomplete
picture of CFTR function and expression patterns in airway
epithelium. We can at present not be sure which cells, and
how many of these we have to transduce to obtain clinical
benefit. However, several requirements of the gene therapy
vector system can be formulated [3,4]. The therapeutic gene
should at least be expressed in the epithelial cells that are
known to express CFTR, preferably at levels comparable to
the endogenous gene. Studies in animal models suggest that
transduction of 5–10% of the target cells would be suffi-
cient for clinical benefit [6]. Moreover, expression should be
stable, preferably life-long. The vector should be efficient
and safe, not only for the patient but also for the environ-
ment. Importantly, the vector and its clinical application
should be affordable, which may turn out to be the greatest
challenge.3. Barriers for gene delivery and ways around them
Living organisms are generally well protected by intra-
and extracellular barriers against invasion of foreign genetic
material. This is required to ensure the genetic stability of
the species. Therefore, GDS has to be designed to overcomethese barriers. A GDS generally consists of a polynucleo-
tide, encoding the therapeutic gene, and a carrier. The carrier
has several important properties. First, it condenses the
polynucleotide, protecting it from mechanical stress and
enzymatic attack. Second, the carrier should facilitate trans-
port of the therapeutic gene from the extracellular space into
the nuclear compartment, where transcription can take
place. In nature, specialists in gene delivery have evolved,
namely viruses. In many different shapes and molecular
designs, viruses consist of a polynucleotide genome pack-
aged in a protein complex called a capsid. The capsid
proteins are well adapted to allow efficient binding to target
cells, penetrate the plasma- or endosomal membrane, and
facilitate intracellular transport and subsequent import of the
genome into the nucleus. While viruses have found different
solutions to this trafficking problem, they all make use of
innate cellular transport systems through interactions of
their capsid proteins with the host. By replacing part of
the viral genome with a therapeutic gene, we can create a
recombinant virus, which can be used as a gene delivery
system. Alternatively, we can make synthetic carriers that
mimic the properties of viral capsids, to package and deliver
therapeutic genes.
Depending on the method of administration, the vector
needs to penetrate several host-defense mechanisms. When
injected into the bloodstream, circulating antibodies and/or
complement factors may inactivate the vector [7–9]. One
lesson learned in a more than a decade of painstaking
preclinical and clinical research is that intact differentiated
airway epithelium in situ is a difficult target for every GDS
developed so far [4]. Vectors delivered to the lumen of the
airways face a spectrum of host defense mechanisms,
including a mucus layer that is continuously cleared by
cilliae, and scavenging macrophages. Further, the receptors
that pathogen derived GDS such as adenoviral vectors rely
on are usually inaccessible, located on the basolateral
membrane and shielded from the external milieu by tight
junctions. Synthetic vectors that are internalised with high
efficiency by epithelial cells in vitro prove much less
effective in vivo [4].4. Viral vectors
Gene delivery systems have been derived from various
viruses. Adenoviral [10], adeno-associated viral [11], lenti-
viral vectors [12,13], poxvirus [14,15], Sendai [16] and
herpes virus [17] are investigated for gene transfer. In
general, the main advantage of viral vectors is the high
transduction efficiency in vivo, compared to current syn-
thetic systems. Further, the use of integrating viral vectors
such as Adeno-associated virus (AAV) and lentiviral vectors
would allow stable expression in the targeted cell pool [18].
This is an important property that none of the available
synthetic systems can offer. On the down side, viral-based
gene therapy poses serious safety concerns. Administration
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either mediated by circulating antibodies or by activation of
complement and macrophages [19–21]. This response can
range from a relatively mild acute inflammation to an
escalated and fatal response, as was observed after intrave-
nous administration of a high dose of adenoviral vector to a
patient [22]. Further, a cytotoxic T-lymphocyte response can
develop against cells that produce viral antigens encoded by
the vector [10]. Apart from the fact that this presents a
health risk to the patient, it greatly reduces the stability of
expression of the vector, and precludes the possibility of
repeatedly delivering viral vectors to compensate for any
fall-off in expression. Another concern is that the vector
inevitably shares genetic information with the wild type
viral genome, which may give rise to recombination events
or activation of the vector in the presence of a wild type
virus. When integrating vectors are used, there is a risk of
germ cell transduction and of insertion mutagenesis. Indeed,
recently two patients treated with bone marrow cells trans-
duced with a retroviral vector were diagnosed with leukemia
caused by an insertional modification of a protooncogene
[23,24]. With these concerns in mind, novel and improved
viral systems are being developed.5. Adenoviral vectors
The first viral GDS for the treatment of CF that was
tested in primates and clinical trial was the adenoviral
vector. It was a logical, if not inescapable choice. The
parent virus is a relatively benign pathogen with a taste for
airway infections, able to efficiently transduce nondividing
cells. Furthermore, the genome of the adenovirus and its
functions had been thoroughly studied; it could be manip-
ulated easily and there were no limitations to the amount of
vector that could be produced. Though this vector has
recently fallen out of favour for reasons explained below, it
is worthwhile to study its history. Many of the drawbacks
of the adenoviral vector system are also encountered to
some extent with other GDS. In the first versions of the
adenoviral vector, the therapeutic gene replaces part of the
viral genome. Replication of the vector is achieved in a
production cell line that provides the missing viral genes in
transit. This approach leaves the viral genome intact but
partially transcriptionally inactive. One of the problems
with this vector system is that low level residual expression
of viral genes can result in a cytotoxic T-cell response,
which targets the cells containing the vector [10]. Further,
the fact that adenovirus is a common airway pathogen is a
mixed blessing. Many potential recipients have circulating
antibodies that may reduce vector efficacy and add to the
T-cell response. Most importantly however, systemic ap-
plication of an adenoviral vector causes an acute, and
potentially life threatening inflammation response, mainly
caused by activation of professional antigen presenting
cells [19,25–27].Adenovirus and adenoviral vectors bind to the cell
following two sequential receptor interactions: first the
capsid fiber binds to a glycoprotein of the immunoglobulin
family called Coxsackie Adenovirus Receptor (CAR) [28]
and second, the fibronectin-binding integrin (integrin v 5)
binds to the penton base capsid protein [29]. These recep-
tors are located at the basolateral membrane of intact
polarised airway epithelial cells [30]. This limits the infec-
tion efficiency of adenoviral vectors when applied to the
airways. This can potentially be cured by replacing the
receptor binding elements of the capsid [31–33]; however,
this has not yet resulted in a vector that targets airway
epithelium.6. Minimal adenoviral vectors
The first generation of adenoviral vectors has been
extensively modified to reduce their immunogenicity. This
was achieved by removing parts of the viral genome, and
providing these genes in transit in a suitable production cell
line. In the most extreme case, only the viral terminal
repeats are retained in the vector backbone (‘minimal’,
‘high capacity’ or ‘gutless’ adenoviral vectors) [34]. This
completely abolishes the expression of viral proteins by the
vector. In animal models, this strongly reduces the cytotoxic
T-cell response against infected cells, and increases the
duration of therapeutic gene expression dramatically
[34,35]. While this is a very promising result, all available
efficient production systems yield vector particles contam-
inated with helper virus. Moreover, for effective use of gene
therapy of CF the vector should be re-targeted to the apical
surface of epithelial cells. Further, circulating antibodies and
acute inflammation responses are still of concern with
minimal adenovectors.7. Lentiviral vectors
Lentiviral vectors are derived from the human immuno-
deficiency virus (HIV)-1 retrovirus, the etiologic agent of
acquired immunodeficiency (AIDS), or from counterparts of
other species. These vectors have advantages compared to
many other gene delivery systems [12,13]. It is an integrat-
ing retrovirus with a considerable cloning capacity (8–9
kb). Current results suggest that stable and cell specific
expression can be obtained using appropriate regulatory
sequences, in particular locus control regions (LCRs) [36].
Third generation or ‘self-inactivating’ vectors were gener-
ated that contain less than 5% of the original viral genome
and cannot be rescued by wild type virus. The limitations of
this approach are that production of large batches of clinical
grade vector is difficult. Lentiviral vectors pseudotyped with
the commonly used vesicular stomatitis virus (VSV)-G
envelope protein are not able to transduce intact polarised
airway epithelia in situ efficiently when administrated to the
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vectors were pseudotyped with apical membrane-binding
envelope proteins, leading to the development of a filovirus-
pseudotyped feline lentiviral vector that efficiently transfect
airway epithelia in vivo [39]. A further challenge will be to
provide the vector with a suitable promoter/enhancer struc-
ture. Finally, risk of insertional mutagenesis and protoonco-
gene activation inherent to all randomly integrating vectors
has to be addressed.8. AAV
Adeno-associated virus has been used to create a GDS
with interesting properties [11,40]. AAV vectors are small
DNA viruses able to transduce nondividing cells. They can
integrate into the genome of the target cell, though with
lower efficiency and specificity than the parent virus. The
vector has a relatively small cloning capacity (4–5 kb),
which makes it difficult to create a vector that produces
CFTR (the open-reading frame alone spans 4443 bp) under
a cell specific promoter/enhancer structure. However, recent
data suggest that it might be possible to overcome this
problem by making use of homologous recombination
between two partial vectors [41].
A receptor (heparan sulfate) for AAV has been located on
the basolateral membrane of airway epithelial cells [42]. The
apical membrane exposes an abundant high affinity receptor
which contains sialic acid in an a-2,3 linkage. The different
vector capsid serotypes vary in sialic acid linkage specificity
[43,44]. So far AAV6 type vectors appear to be most
effective in airway epithelia [45].
Clinical trials (Phases I and II) with different AAV
serotype vectors are being performed [46,47]. Initial results,
including data submitted or in press, confirm the low
toxicity and immunogenicity ascribed to the system. Effec-
tive titres in lung tend to be disappointing, however,
presumably due to intracellular inactivation and limited
access to apical receptors. It is not clear yet whether level
and stability of transcription obtained with available vectors
will be sufficient for clinical benefit.9. Sendai virus
A most recent addition to the viral vector repertoire is
recombinant Sendai virus. Recombinant Sendai virus was
shown to be very effective in transduction of airway epithe-
lial cells in situ both in mice and ferrets [48,49]. The ferret
lung is considered a better model than mice since the
architecture of distal airways and the frequency of submu-
cosal glands more closely mimics the human situation [50].
Despite this encouraging result, it is clear that many of the
concerns raised against other viral GDS still have to be
addressed, particularly how Sendai can be administered
repeatedly without provoking immune ablation.10. Synthetic vector systems
Synthetic GDS consist generally of DNA encoding the
therapeutic gene, combined with a carrier. This type of
vector is theoretically the method of choice, since many of
the safety issues involved with the use of viral vectors could
be avoided, and it can potentially package any size of DNA.
The DNA is usually in the form of a plasmid encoding the
therapeutic gene, which can be isolated from bacteria in
large amounts and in clinical grade. The carrier is generally
a synthetic compound, which mimics the functions of a viral
capsid, but should lack its immunogenicity. It condenses the
DNA, binds to cells, and helps the vector to escape from the
endosomal compartment. Like we have seen with viral
vectors, systemic delivery of synthetic GDS has to over-
come many barriers, from the complement system to the
nuclear membrane. While this development is of major
interest, much work needs to be done to accomplish its full
therapeutic potential. We will describe a number of these
systems that may be of interest to CF researchers. The
CFTR Working Group online repository presents a number
of basic protocols and contacts that may offer both the
novice and experienced GDS researcher an entry into this
complex field [5].
Carriers generally contain either cationic lipids or cat-
ionic polymers, which bind with high affinity and thus
condense the negatively charged DNA. Although many
carriers have been used successfully in vitro, their in vivo
use is less straightforward. Initial studies and clinical trials
that targeted airway epithelia were performed with cationic
liposomes. Proof of principle was established; marker genes
and CFTR could indeed be expressed in this way [51].
However, these initial studies also showed that these carriers
lacked efficiency in vivo, further the available plasmid
vectors could not establish stable expression in the correct
cell specific pattern.11. Uptake and intracellular transport of synthetic GDS
Non-viral gene delivery systems rely on cellular uptake
mechanisms. Polycations complexed to DNA result in
positively charged polyplexes that interact electrostatically
with negatively charged proteoglycans of the cell mem-
brane, followed by endocytosis [52]. This nonspecific mode
of cell entry can be altered by the addition of a targeting
ligand to the DNA delivery vehicle. The first targeting
ligand used was asialo-orosomucoid for hepatocytes [53].
Numerous ligands are under investigation [54], including
transferrin [8], folate [55,56], monoclonal antibodies [57],
invasin [58] and carbohydrates [59]. To enhance specificity
of uptake, attempts are made to shield the cationic aspect of
the complexes with polyethylene glycol (PEG) moieties
[8,56,60]. However, the apical membrane of intact epithelial
airway cells still proves a formidable barrier to viral and
non-viral vectors alike, which should not surprise us since
D. Klink et al. / Journal of Cystic Fibrosis 3 (2004) 203–212 207this is the most well-guarded frontier that separates us from
our hostile environment.
One practical solution is to deliberately break down this
barrier, by damaging the target tissue with irritants like SO2
[37], EGTA or fatty acids [61,62]. This results in a transient
dissociation of tight junctions, which is associated with
exposure of basolateral epitopes and increased endocytotic
activity. Indeed, early success with cationic liposomes in
animal studies was probably caused by this effect. Whether
this approach is acceptable in a clinical context remains to
be established.
Non-viral vectors have mechanisms to circumvent lyso-
somal degradation, though much less efficient than virus
derived GDS. Polycationic polymers, such as polyethyleni-
mine [63] and pDMAEMA [64], are able to escape the
endosome due to intrinsic properties of the polymer. First,
the high buffer capacity of the compounds would result in
swelling of the endosomes as the lysosomal proton pump
attempts to reduce the luminal pH. Further, cationic poly-
mers tend to destabilize membrane in high concentrations.
However, the bulk of the DNA delivered this way does not
escape hydrolysis and this remains one of the bottlenecks in
delivery by synthetic GDS. In contrast, the gene transfer
activity of the cationic polymer polylysine based com-
pounds is low, unless endosomolytic agents are present
[65]. Pharmacological agents such as chloroquine can be
used to disrupt the internal routing of the GDS from the
early endosomes to the lysosomal compartment [66]. In-
deed, the presence of chloroquine enhanced transfection
efficiency of lactosylated polylysine considerably [67].
Chloroquine is a weak base (pKA 8.1 and 10.2) that
accumulates in acidic cellular compartments. Common
consensus is that due to the raised luminal pH, osmotic
swelling occurs followed by the destabilization of the endo-
somal membrane and release of the contents into the cytosol
[68]. Another strategy to promote endosomal release is the
addition of endosome-disrupting peptides such as N-termi-
nal amphilic anionic peptides derived from hemagglutinin
[69,70] and glutamatic acid–alanine–leucine–alanine (GA-
LA) [71,72]. Glycerol is another agent that promotes endo-
somal escape [73]. KALA (lysine– alanine– leucine–
alanine) is a cationic amphipathic peptide and was designed
to both condense DNA and destabilize the endosomal
membrane [74].
Once released from endosomes, the DNA has to reach
the nucleus. Little is known about how current synthetic
gene delivery vehicles move within the host cell. They may
diffuse freely through the cell or move actively (‘‘piggy-
backing’’) after association with own intracellular carriers
the host cell. The network of actin or tubulin filaments
provides an intracellular transport system that is exploited
in various ways by viral and bacterial pathogens for
transport from the periphery to the nucleus. It seems
attractive to apply the same strategy to future synthetic
systems. This is one of the reasons why cationic polymers
that can be covalently linked to synthetic peptides, carbo-hydrates and proteins are of major interest to synthetic GDS
development.12. Nuclear import, a major barrier in non-viral gene
transfer
Once in the perinuclear region, the foreign DNA must
enter the nucleus to undergo transcription. The nucleoplasm
is separated from the cytosol by the nuclear envelope, which
consist of an outer and inner nuclear membrane. Very large
and complex protein structures called nuclear pore com-
plexes (NPC) form aqueous channels through the double
nuclear membrane and thus create passageways for proteins
and genetic material [75–77]. Small molecules, up to 9 nm
in diameter or proteins up to 50 kDa, can passively diffuse
through the NPC, but larger cargo (up to 28 nm in diameter,
or f 1000 kDa) is transported in an active signal-mediated
manner. Nuclear localization signals (NLS) on the cargo
bind to cytoplasmatic proteins such as a-importins and
transportin, which are responsible for docking the cargo
onto the NPC. The vectorial translocation into and across
the NPC is still under intense study. A key regulatory
molecule, the GTPase Ran, has been reported to be essential
for the creation of a concentration gradient [78].
In principle, there are two ways for viral and non-viral
vectors to deliver their genetic material into the nucleus.
First, the vector resides in the cytosol until the nuclear
envelope is disassembled during mitosis. The vector ge-
nome can then enter the newly assembling nuclei of the
daughter cells. Alternatively, the genomic material can be
delivered by active transport through the envelope of the
interphase nucleus [79]. Many viruses have developed
clever devices to use the nuclear transport systems of the
host to transport their genome through the nucleopore into
the nuclear compartment [80–83], which allows them to
transduce nondividing cells efficiently. It is especially in
this aspect that non-viral transfer systems are deficient,
they are much more effective in mitotic cells than in non-
mitotic cells. As the DNA double helix has a diameter of
2–3 nm (nonhydrated) and turns of the double helix well
below 28 nm are possible, transport seems feasible in
principle. However, there is no known active transport
system for DNA in the cytoplasm. Evidence was presented
supporting the hypothesis that nuclear uptake of intact
vector DNA can occur exclusively in cells entering mitosis,
following breakdown of the nuclear membrane [69,84].
However, it was also reported that transferrin/polylysine
complexes used for gene transfer in the presence of
glycerol gave high transgene expression levels in growth-
arrested fibroblasts [85]. Pollard et al. [86] reported that
some polycations facilitate the nuclear uptake of DNA
complexes. In vitro, plasmid DNA is thought to form a
complex with proteins prior to transit to the NPC and
translocation [87]. Likewise, it has been shown that single-
stranded DNA/protein complexes were efficiently imported
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dependent nuclear import pathway [88]. Moreover, several
groups have reported a significant increase in transfection
efficiency after inclusion of an NLS in the carrier system
[89–91]. Unfortunately, none of these studies appear
completely conclusive. Firstly, in transport studies with
fluorescently-labelled DNA, fragmentation of the DNA
prior to nuclear transport cannot be excluded. Small
DNA fragments ( < 500 bp) may readily accumulate in
the nucleus, in contrast with larger molecules that can
accommodate a therapeutic gene. Second, in experiments
with supposedly ‘non-mitotic cells’ actual controls of
mitotic activity after addition of the vector are often
missing. It should be noted that non-viral GDS are gener-
ally cytotoxic, application of which can easily result in a
burst of transient mitotic activity. Therefore, much of the
confusion could be resolved by using a simple but rigorous
device to monitor transfection: continuous time-lapse fluo-
rescence microscopy. This way we can establish without
question whether cells that express the vector have, or have
not been in mitosis after application of the vector (D. Klink
et al., unpublished results). If there is any consensus in this
field, it is that none of these developments have yet
resulted in a synthetic GDS that demonstrably works
sufficiently well in intact airways in vivo, the prime target
of CF gene therapy [4].13. Transfection of epithelial cells in culture
As outlined above, a variety of synthetic GDS ranging
from cationic liposomes to modified cationic polymers is
available to the researcher. Many of these are commercially
available and work well in immortalised cell lines. The
online repository presents a number of basic protocols that
can be used as a starting point for further exploration [5].
These include the use of liposome carriers [92] and various
cationic polymers [93]. It follows from the discussion of
uptake and intracellular transport of synthetic GDS that their
efficacy is largely determined by the properties of the target
cells. In general, mitotically active nonpolarised cells are
much easier to transfect than polarised quiescent cells.
Therefore, in addition to a careful titration of DNA-carrier
ratios and carrier-cell number ratios, optimal conditions for
growth and carrier uptake should also be defined. For this,
the reader is referred to other papers this issue [94–97] and
the repository that describe the properties of epithelial cell
lines [5] and primary culture systems [98].14. The therapeutic gene, the longer the better?
So far, we have concentrated on the carrier rather than the
therapeutic gene. Gregory et al. [99] showed proof of
principle for CFTR expression by gene delivery. Initial
experiments with human CFTR cDNA constructs werehampered by the presence of a cryptic prokaryotic promoter
at position 930 of the hCFTR mRNA, which severely
reduced the viability of the bacterial host. This problem
was solved by mutating a single nucleotide in an open-
reading frame (ORF)-neutral way. In later versions of
hCFTR expression vectors, improving the cloning stability
of the constructs and leaving the protein sequence intact
[100,101]. A set of such hCFTR cDNAs, including several
mutant versions has been made by Dalemans et al. (Trans-
gene, Strasbourg, France). Many early studies were per-
formed with a simple construct comprising a full-length
CFTR cDNA and a ubiquitously expressed promoter. The
advantage of this approach is that such constructs are
relatively small, and can therefore be produced in large
quantities and in clinical grade. However, a CF gene therapy
vector has to be expressed in a stable and cell-specific
manner, which requires more sophisticated expression con-
structs, in particular transcription control units. The expres-
sion pattern of the CFTR in airway cells is complex. Not
only do different cell types express CFTR to different levels
[102], also this expression pattern is subject to modulation
during inflammation and remodelling [103]. Progress has
been made using a promoter/enhancer structure derived
from the cytokeratin (CK) 18 gene, which has an expression
pattern similar to CFTR [104]. However, this kind of core
promoter/enhancer constructs does not exactly mimic the
responses of the endogenous CFTR gene. Further, they are
subject to transcriptional silencing by methylation and
chromatin remodelling (positional silencing). Another issue
is that these full-length cDNA constructs do not have an
intron structure, which results in inefficient mRNA process-
ing and missing regulatory sequences. Most importantly,
plasmid derived vectors are not chromosomes: they do not
have telomers and centromers, and lack efficient eukaryotic
replication sites. As a result, these vectors are intrinsically
instable in a population of mitotic cells.
The obvious solution to all of these problems is to create
a true mini-chromosome complete with centromere and
telomeres, encoding the complete human CFTR gene,
including distant regulatory sequences and boundary ele-
ments. This proves to be a daunting task, however. The
CFTR gene is very big, some 200,000 base pairs excluding
flanking control elements. In addition, it seems possible that
small chromosomes ( < 1 Mb) might not be stable. A vector
this size is very difficult to handle in bacterial plasmid
vectors and with standard molecular biological techniques.
Yeast artificial chromosomes (YAC) containing the human
CFTR locus (Chr 7q31) were isolated shortly after the
identification of the CFTR gene [105]. However, yeast
elements are not stable in higher eukaryotes. Several groups
created large replicating CFTR mini-chromosomes, using
different approaches. In the ‘top down’ approach, existing
mammalian chromosomes are used or further fragmented,
and retro-fitted with a gene of interest by recombination in
cultured mammalian cells. One such pre-existing mini-
chromosome derived from human chromosome 1 was
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CFTR could be shown in cultured cells [106]. A circular
chromosomal vector into which large fragments can be
fitted by Cre/Lox recombination was described and reported
to be stable in the mouse germ line [107]. In the ‘bottom up’
approach, bacterial or yeast vectors are used to provide
mammalian centromeric and telomeric sequences [108].
Huxley et al. created a hybrid vector based on a YAC
encompassing the CFTR gene and a viral element, Ori-P/
EBNA-1, that ensures replication and mitotic segregation in
mammalian cells [109]. Another approach avoiding the use
of viral replication elements and antigens is to add human
centromeric sequences, i.e. long arrays of alpha satellite
tandem repeats ( > 100 kb), which can be stably cloned as a
unit copy bacterial plasmid (P1 phage-based artificial chro-
mosome, PAC), and human telomere sequences [110].
These developments may lead to a vector that stably
segregates during cell division as a low copy episomal
element, carrying a large chromatin context for cell specific
expression. Such a PAC has been engineered to contain a
large region of the CFTR gene (140 kb) including its natural
promoter, fused to a synthetic exon encoding eGFP. Ex-
pression from the CFTR promoter by RT-PCR, splicing of
all 10 exons, and correct translation of the expected CFTR–
GFP fusion protein as well as reliable detection of a stable
copy has been demonstrated in mammalian cells (Schindel-
hauer et al., submitted for publication). However, efficient
transfer of such large genetic elements to relevant target
cells in a patient requires the development of a novel
transfer technology. In a complementary study, PACs con-
taining up to 180 kb of genomic CFTR fused to CFTR
cDNA have been constructed which encode the whole
CFTR gene and have been shown to express CFTR mRNA
after in vitro transfection into epithelial cells [111].15. Future developments
For monogenetic hereditary diseases, gene therapy offers
the potential of correcting the underlying cause for which
the responsible gene is known. Since delivery of a CFTR
gene in the relevant cells, at the right time, and at the proper
expression level seems difficult to achieve with available
vector systems, alternatives should be considered. One such
alternative is to correct the CF mutation by homologous
recombination with a small DNA fragment that encodes the
correct sequence [112,113]. This would circumvent many
problems associated with stable and functional gene deliv-
ery and result in a pool of normal progenitor cells in the
targeted organ. So far, the problem with this approach in CF
therapy is the low conversion frequency plus the fact that
the few corrected cells have no significant proliferation
advantage. Exaggerated inflammation, associated with tis-
sue damage and fibrosis, is a hallmark of CF lung pathology
[114]. Delivery of a GDS encoding an extracellular modu-
lator of these processes, e.g. an interleukin, could perhaps beeffective and more easily achieved [49,115,116]. Recent
developments indicate that the delivery of dsDNA is not the
only possible application of delivery systems. RNAi and
RNA decoys that bind regulatory proteins can be used to
modulate gene expression of relevant genes [117]. This
could lead to a novel therapeutic approach that aims at
modulating the inflammation response and the subsequent
fibrotic process in CF and related chronic lung disease
(asthma, chronic obstructive pulmonary disease, COPD,
bronchiectasis).References
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